Frontiers in Oncology (Dec 2021)

A Novel Blood Index-Based Model to Predict Hepatitis B Virus-Associated Hepatocellular Carcinoma Recurrence After Curative Hepatectomy: Guidance on Adjuvant Transcatheter Arterial Chemoembolization Choice

  • Yiping Zou,
  • Yiping Zou,
  • Zhihong Chen,
  • Zhihong Chen,
  • Qi Lou,
  • Qi Lou,
  • Hongwei Han,
  • Hongwei Han,
  • Yuanpeng Zhang,
  • Zhenrong Chen,
  • Zuyi Ma,
  • Zuyi Ma,
  • Ning Shi,
  • Haosheng Jin,
  • Haosheng Jin,
  • Haosheng Jin

DOI
https://doi.org/10.3389/fonc.2021.755235
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundPostoperative recurrence is a significant obstacle in hepatocellular carcinoma (HCC) treatment. This study aimed to construct a blood index-based model to predict hepatitis B virus-associated HCC (HBV-HCC) recurrence after curative hepatectomy.MethodsA total of 370 patients who received initially curative hepatectomy for HBV-HCC were included in this study. A novel blood index signature (BIS) was identified and systematically analyzed for its recurrence predictive value. Following this, multivariate Cox regression analysis was performed to build a blood index-based nomogram.ResultsA BIS based on the aminotransferase-to-platelet ratio index and a systemic inflammatory response index was used to construct a nomogram. The model showed good clinical applicability and reliability. Notably, the patients in the high recurrence risk group tended to benefit from adjuvant transcatheter arterial chemoembolization (TACE).ConclusionA reliable model was constructed to predict the HBV-HCC recurrence after curative hepatectomy. This model can guide the surgeons in selecting patients with high recurrence risk patients who may benefit from adjuvant TACE.

Keywords